Anti-tumor necrosis factor-a (TNFa) therapy has improved the prognosis of many chronic inflammatory diseases. It appears to be well-tolerated by liver-transplant patients. However, their use and their safety in kidney-transplant patients have yet to be determined.
Introduction
The advent of tumor necrosis factor-a (TNFa) inhibitors (antiTNFa therapies) within the past decade has resulted in a revolution in the management of severe chronic rheumatoid (psoriatic arthritis, ankylosing spondylitis, or rheumatoid arthritis), gastrointestinal (Crohn disease and ulcerative colitis), and dermatologic (psoriasis) inflammatory diseases.
TNFa is a pleiotropic cytokine produced by immune cells (macrophages, dendritic cells, and T lymphocytes). [1] TNFa binds to 2 surface receptors, namely, TNFR1 and TNFR2, and activates different signaling pathways associated with cell proliferation; inflammation induction, immune modulation, and proinflammatory cytokine production; and cell apoptosis. [1, 2] Very few studies regarding the use of anti-TNFa therapy in kidney transplant patients have been conducted. Organ transplant patients have been excluded from anti-TNFa drug safety studies due to the increased risks of infection [3] and cancer specific to this population. [4, 5] Anti-TNFa treatment is associated with an increased incidence of severe bacterial, [6, 7] viral (i.e., herpesvirus), [8] and opportunistic (i.e., tuberculosis) [9, 10] infections and may cause certain cancers. [11] Anti-TNFa drugs also cause hypersensitivity reactions, which may contribute to autoimmune disease development, particularly drug-induced lupus. [4] To date, the literature includes only case series regarding organ transplant patients treated with anti-TNFa drugs. [12] [13] [14] [15] [16] [17] [18] Editor: Luisa Guidi.
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We retrospectively evaluated 16 kidney transplant patients treated with anti-TNFa drugs for chronic inflammatory diseases. Our study objectives were to describe the indications for anti-TNFa treatment, the responses to treatment, and the safety of these drugs in this population of immunocompromised patients.
Patients and methods

Methods
This multicenter retrospective observational study was conducted in 7French kidney transplant centers. We identified 16 patients (11 male) aged 46.5 years (34-51.8) from the ASTRE prospective database of the Spiesser Kidney Transplantation Group (Angers, Caen, Clermont-Ferrand, Reims, and Strasbourg University Hospitals) and the DIVAT prospective database (Necker and Toulouse University Hospitals). Patients aged at least 18 years who had undergone kidney transplantation and received anti-TNFa treatment were included in this study. The ethical committee of the institution approved the extraction of data from the patient charts.
Patient medical charts and demographics were retrieved from the hospital registries, and the following data were recorded: age, gender, nephropathy, past history of infection or malignancy, date of transplantation, and postoperative immunosuppressive regimen. We examined the kidney transplantation outcomes of these patients, including patient and graft survival, occurrence of acute rejection episodes, infections, cancer, adverse event with TNF therapy, causes of graft loss, and patient death. The glomerular filtration rate (GFR) was estimated (eGFR) using the Modification of Diet in Renal Disease 4 (MDRD4) formula. Failing data were retrospectively found in the patient record.
Statistics
All analyses were performed using Stata software (version 13, StataCorp, College Station, TX) and were performed for a 2-sided type I error of a5%. Baseline characteristics are presented as the mean ± standard deviation (SD) or the median (interquartile range) for continuous data (assumption of normality assessed via the Shapiro-Wilk test) and as numbers and percentages for categorical data. Quantitative variables were compared between independent groups (infection yes/no and death yes/no) by Student t test or the Mann-Whitney U test if the conditions of the t test were not met (normality and homoscedasticity were analyzed using the Fisher-Snedecor test). When appropriate, comparisons between independent groups were analyzed using a Chi-squared test or Fischer exact test for categorical variables. The relationships between quantitative outcomes were analyzed using correlation coefficients (Pearson or Spearman, according to the statistical distribution). Regarding the evolution of the eGFR (longitudinal repeated data), randomeffects models were used to account for between-and withinpatient variability. Finally, due to the design of this study (metaanalysis of individual data), these analyses were completed using generalized linear mixed models (logistic regression for dichotomous dependent variables: infection yes/no and death yes/no) to study the fixed effects described previously, and the study was considered a random effect (to measure between-and withinstudy variability). Given the sample size, no meta-regression analysis was performed based on the results of the multivariate analysis. Last, sensitivity analysis was performed to measure the impact of missing data.
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . Prior to kidney transplantation, 2 patients developed neoplasms (breast adenocarcinoma and basal-cell carcinoma), and 3 patients developed serious infections requiring hospitalization. The 1st patient (P#14) developed 3 bacterial infections (urinary tract, gastrointestinal, and cutaneous) during his 1st kidney transplantation, the 2nd patient (P#7) developed eye shingles, and the 3rd patient (P#10) developed dialysis catheter-related staphylococcal septicemia.
Five patients began anti-TNFa treatment before kidney transplantation (Table 1) . Three patients (P#4, P#5, and P#15) discontinued treatment following transplantation before resuming it at 4, 6, and 22 months, respectively, after transplantation ( Table 2) . Patients P#9 and P#14 continued their treatments, which they had initiated at 15 and 42 months, respectively, prior to transplantation (Table 2) .
Cytomegalovirus prophylaxis was administered to 4/8 patients (50%) at risk for viral reactivation or primary graft infection upon anti-TNFa treatment initiation. Seven patients (44%) received Pneumocystis pneumonia prophylaxis (trimethoprim/sulfamethoxazole) upon anti-TNFa treatment initiation. 
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The indications for anti-TNFa treatment were rheumatoid (n = 5, 31%), gastrointestinal (n = 8, 50%), and dermatologic (n = 1, 6%) disease, as well as microscopic polyangiitis (n = 1, 6%) and familial Mediterranean fever (n = 1, 6%) ( Table 2 ).
Clinical response to anti-TNFa treatment
Overall, clinical responses were observed by clinicians in 13/16 cases. A complete response was observed in 9 cases (56%), and a partial response was observed in 4 cases (25%) ( Table 2) . Two complete responses (40%) and 2 partial responses (40%) were noted in patients with chronic rheumatoid disease (n = 5); 5 complete responses (62.5%) and 2 partial responses (25%) were noted in patients with chronic inflammatory bowel disease (n = 8); 1 complete response was noted in a patient with pustular psoriasis, resulting in adalimumab discontinuation at M48; and 1 complete response was noted in a patient being treated for microscopic polyangiitis. One patient (P#15) with AA amyloidosis discontinued treatment at M1 due to a urinary tract infection; thus, anti-TNFa treatment effectiveness could not be determined in this patient.
Infectious complications
Eight patients (50%) developed 23 serious infections while receiving anti-TNFa treatment (1.43 infections per patient) (Tables 3 and 4 ). These patients mainly developed bacterial infections (n = 16) (primarily upper urinary tract infections and acute cholecystitis), although viral infections (n = 4) (varicellazoster virus [VZV], cytomegalovirus, and BK viremia) and a fungal infection were also noted. On univariate analysis, the mean ages of the patients who did and did not develop infection were 51.1 ± 6.4 and 36.8 ± 18.3 years, respectively, P = 0.06 (Table 4) . Induction therapy, corticosteroid doses ≥ 10 mg, and ABMR = acute antibody-mediated rejection, Ada = adalimumab, ARDS = acute respiratory distress syndrome, AS = ankylosing spondylitis, Cert = certolizumab, CR = complete remission, d = day, Eta = etanercept, F/U = follow-up, HD = hemodialysis, Inf= infliximab, KT = kidney transplant recipients, M = month, TCMR = acute T cell-mediated rejection, TNFa = tumor necrosis factor-a, UC= ulcerative colitis. * Anti-TNFa therapy introduced and stopped before kidney transplantation. Table 3 Description of severe infectious complications that occurred during anti-TNFa therapy. IBD = inflammatory bowel disease, IQR = inter-quantile range, KT = kidney transplantation, NS = not significant, TNFa = tumor necrosis factor-a.
Garrouste (Table 4) .
Cancer
Four patients (25%) developed cancer while receiving anti-TNFa treatment ( Table 2 ). Three patients with chronic inflammatory bowel disease developed a solid tumor or multiple solid tumors after biological therapy initiation. These included 1 case of lung adenocarcinoma at M12, which resulted in infliximab discontinuation at M14 (P#6 was still alive at the last follow-up at M20); 2 basal-cell carcinomas at M46 and M48 (P#12); and a papillary adenoma of the kidney at M23 (P#13 died of septicemia at M26). P#2 developed Hodgkin lymphoma at M32, which resulted in anti-TNFa treatment discontinuation. Table 2 ). Two patients (12.5%) lost their grafts. The 1st, P#15, developed AA amyloidosis recurrence in the graft at M29 of anti-TNFa treatment despite certolizumab treatment. The 2nd, P#11, who exhibited donor-specific antibodies before anti-TNFa treatment, lost the graft (Table 2 ) at M18 (58 months after transplantation) due to antibody-mediated rejection. The patient had been receiving adalimumab for Crohn disease and developed a cutaneous rash while receiving infliximab treatment (M1.5), which resulted in the initiation of adalimumab treatment. A graft biopsy performed at M3 due to increased blood creatinine levels revealed an inflammatory infiltrate occupying 25% to 30% of the biopsy and signs of t1 tubulitis consistent with either borderline rejection (Banff 2007) [19] or acute tubulointerstitial nephritis. High-dose corticosteroid therapy and anti-TNFa treatment discontinuation improved graft function. Adalimumab was subsequently resumed at M6. A biopsy conducted at M8 due to further graft function deterioration and increased Luminex preexisting donor-specific antihuman leukocyte antigen antibody (DQ7) mean fluorescence intensity showed acute antibodymediated rejection (g1 + ptc2). [19] No treatment reduction was observed (cyclosporin A, azathioprine, and steroids) after anti-TNFa treatment initiation, nor was treatment reduction observed during the preceding 3 months.
Patient survival
Overall, 5 patients died a median of 28 months (1-71) after antiTNFa therapy initiation (Table 2) . Two patients died of bacterial infections. One of them (P#3) died of septic shock of gastrointestinal origin at M10 of anti-TNFa treatment despite treatment discontinuation at M5 due to gangrenous cholecystitis accompanied by biliary peritonitis. The 2nd developed multiple infections, including 2 bacterial infections, 1 BK viral infection, and 1 candidal infection. He died of a bacterial infection at M29. Two patients died after anti-TNFa treatment was discontinued. P#15 lost the renal graft at M20 due to AA amyloidosis recurrence and died at M28 of cardiac AA amyloidosis. Patient P#16, who had microscopic polyangiitis, died of intraalveolar hemorrhage at M71 despite treatment discontinuation at M11 following 2 VZV infections, the 1st of which involved the thorax, and the 2nd of which involved the eyes. Another patient (P#4) died of acute respiratory distress syndrome of unknown cause at M1 after anti-TNFa treatment (10 months after transplantation). On univariate analysis, the patients who died were significantly older (58.0 ± 10.2 vs 37.3 ± 12.7 years; P = 0.009) than their surviving counterparts.
Discussion
To our knowledge, our study reports the largest case series of kidney transplant patients treated with anti-TNFa drugs. The clinical response rate noted in our study (13/16 ; 81.3%) is similar to that noted among all solid-organ transplant patients in the literature who received anti-TNFa treatment (29/36; 80.6%) (Tables 5 and 6 ).
However, in our series, we observed a particularly high rate of severe infections (8/16, 50% of patients). Most of these infections were bacterial and resulted in permanent treatment discontinuation in 4 patients ( Table 2) and death in 2 patients. These outcomes have rarely been reported in previous series. Only 1 study, which evaluated liver transplant patients who received anti-TNFa treatment for inflammatory bowel disease, observed a similar infection rate (3/8, 37.5%). [17] Combining the results of our series with those of previously reported series (Table 5) showed that 12/ 52 patients (23.2%) developed infections while receiving antiTNFa treatment. Anti-TNFa therapy administration in patients who have not undergone organ transplantation is associated with an increased risk of bacterial infection, [6, 7] viral reactivation (particularly herpesviruses), [8] and opportunistic infections, especially tuberculosis. [8] This risk seems to be heightened: during the first 3 months after anti-TNFa therapy initiation, [27] is also increased by the presence of underlying disease, and the combination of immunosuppressive treatment and corticosteroids >10 mg/day. [10] This was not observed in our series (Table 4 ). In addition to being more frequent among immunocompromised patients receiving anti-TNFa therapy, infections seem to be particularly severe in these patients. We noted a relationship between infection occurrence in patients receiving anti-TNFa therapy and patient death (4 of 5 patients died, P = 0.04). International guidelines [28] underscore the importance of detecting and treating tuberculosis. It may be necessary: to place kidney transplant patients on antiinfection prophylaxis upon anti-TNFa therapy initiation, in addition to surveilling these patients closely; and to decrease immusoppressive regimen dose (i.e., steroids). In our study, 4 patients (25%) developed either solid tumors (n = 3) or hematologic malignancies (n = 1) ( Table 2) . No patients died as a direct result of these cancers following a median followup of 7 months (2-47). Two other cases of neoplasms following anti-TNFa therapy (6/52 organ transplant patients overall, 11.5%) have been reported in liver transplant patients, 1 case of Epstein-Barr-virus-associated lymphoma and 1 case of colorectal adenocarcinoma ( Table 4 ). The risk of lymphoma and solid tumors (particularly tumors of the skin) is heightened after kidney transplantation, as well as in the setting of inflammatory bowel disease [11, [29] [30] [31] [32] [33] and rheumatoid arthritis. [34] [35] [36] However, patients with spondyloarthritis do not appear to have an increased cancer risk. [37] The relationship between anti-TNFa therapy and cancer is unclear. [38] In patients with inflammatory bowel disease, anti-TNFa therapy may increase the risk of nonmelanoma skin cancer, although this risk is mainly related to thiopurine use, [39] as well as the risk of melanoma, [29] and reduce the incidence of colorectal adenocarcinoma by controlling bowel inflammation. [40] Patients with rheumatoid arthritis receiving anti-TNFa therapy seem to be at greater risk for nonmelanoma skin cancer [41] and melanoma, [42] whereas patients being treated for spondyloarthritis do not seem to have an increased cancer risk. [37] In our study, 2 patients developed breast cancer (À6 years) and basal-cell carcinoma (À9 years), respectively, before receiving anti-TNFa therapy. Neither of these patients relapsed after transplantation. Following kidney transplantation, the risk of cancer recurrence may reach 20% depending on the type of cancer. [43] Therefore, based on the cancer history of the patient, a waiting period may be necessary before kidney transplantation is authorized. [5] Initiating anti-TNFa therapy does not seem to contribute to subsequent cancer recurrence. [44, 45] We observed 1 case of a kidney graft loss (P#11, Table 2 ) at M18 secondary to antibody-mediated rejection in a patient treated with adalimumab for Crohn disease. No cases of organ rejection have been reported in the literature (Tables 5 and 6 ). TNFa and its receptors, TNFR1 and TNFR2, play important roles in kidney transplant rejection. [1] In animals, anti-TNFa therapy may prolong kidney graft survival in the event of rejection. [46] Thus, the abovementioned antibody-mediated rejection was probably unrelated to the use of this drug; thus, we cannot rule out autoimmune adalimumab-induced acute interstitial nephritis at M3. [47, 48] Other autoimmune phenomena with renal manifestations have been reported in the setting of anti-TNFa therapy, namely, lupus [49] [50] [51] and glomerulonephritis. [52] In the literature, two cases of cutaneous lupus have been Table 6 Anti-TNFa treatment for psoriasis or other indications in solid organ recipients, a review of the literature.
Reference Organ transplanted year (IQ) Immunosuppressive regimen Biologic Clinical response Complications
Psoriasis
Brokalaki et al 2012 [23] Pancreas-renal n = 18 Tac/MMF/steroids Etanercept 1/1 None at 2 years Hoover et al 2007 [16] Liver n = 16
Tac/sirolimus Etanercept 1/1 None at 6 months Collazo al 2008 [24] Liver n = 11
Tac/MMF/steroids Etanercept 1/1 None at 5 months Madankumar et al 2015 [25] Liver n = 15
Tac/everolimus/steroids Etanercept 1/1 Multiple angiocholitis Others Leroy et al 2009 [18] Kidney n = 1 CsA/MMF/steroids Infliximab 1/1 None at 8 years Meytas et al 2007 [26] Heart n = 2 N C I n fliximab 2/2 None CsA = cyclosporin A, MMF = mycophenolate mofetil, ND = no data, Tac = tacrolimus, TNFa = tumor necrosis factor-a. [20] Liver n = 1 Tac Infliximab Remission clinic and endoscopic
None
Page et al 2008 [21] Liver n = 1 CsA/Aza Infliximab for 2 years, followed by Ada 1/1 Lupus-like syndrome El-Nachef et al 2010 [13] Liver n = 2; kidney = 1; 6 [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] NC Infliximab n = 3 3/3 Pyelonephritis n = 1
Temme et al 2010 [15] Kidney n = 2 Tac n = 1/CsA n = 1; MMF n = 2; steroids n = 2 Infliximab n = 2 2/2 None
Mohabat et al 2012 [17] Liver n = 8; 3.5 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Tac n = 6/CsA n = 2; Aza n = 3; MMF n = 1; steroids n = 5/8
Infliximab n = 4; infliximab then Ada n = 4
Clinical 6/8; endoscopic 43%
Cryptosporidiosis; clostridium difficile colitis; bacterial pneumonia; EBV-PTLD n = 1 and 1 death Sandhu et al 2012 [12] Liver n = 6; 7 [6] [7] [8] [9] [10] Tac n = 5/CsA n = 1; Aza n = 1; MMF n = 0; steroids n = 3 (50%)
11 CR (65%); 2 PR (12%) 4/6 Systemic lupus erythematous (n = 1); colorectal cancer n = 1 Indriolo et al 2013 [22] Liver n = 3; kidney n = 1
Tac/Aza/steroids n = 1; Tac n = 1; CsA n = 1; Tac/SRL n = 1
Infliximab n = 4 Clinical 3/4; endoscopic 1/3 Moluscum contagiosum n = 1 Schnitzler et al 2015 [14] Liver n = 3; heart n = 1
Tac n = 2; Tac/steroids n = 1; Tac reported in liver transplant patients who received infliximab and adalimumab, respectively (Table 5) , although neither patient presented with kidney involvement. Our study had several limitations. First, the retrospective nature of our study may have resulted in an underestimation of the number of kidney transplant patients who received antiTNFa therapy. Second, because of the small size of our series, the number of indications (chronic inflammatory bowel disease, chronic rheumatoid diseases, or others) for anti-TNFa therapy and the variety of drugs used, only patient age was identified as a risk factor for infection and death (Table 4 ). In the literature, age is an independent risk factor for infection and death in patients with chronic inflammatory diseases, regardless of whether or not these patients have been treated with biological therapy, [53] as well as in patients who have undergone kidney transplantation. [54] On univariate analysis, no other risk factors for infection (i.e., organs transplanted, indications, numbers of concomitant immunosuppressive treatments, or corticosteroid doses) were identified after reviewing all solid-organ transplant patients reported in the literature (Table 7) .
In conclusion, anti-TNFa therapies are effective for treating chronic inflammatory diseases in kidney transplant patients and do not lead to graft function deterioration. However, infection and cancer rates are particularly high among these immunocompromised patients. Regular screening for infection and cancer may thus be recommended for this at-risk population, in addition to antiinfection prophylaxis. Tailoring concomitant immunosuppressive therapy must be investigated in further studies to ensure that anti-TNFa therapy is safe in kidney transplant patients. Table 7 Univariate analysis of infections in solid organ recipients treated with anti-TNFa therapy in the literature and in our study.
Infections
No infections P 
